Compare GSK plc (GSK) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Kinder Morgan Inc — how do they compare? GSK plc trades at $52.4 (market cap $101.34B), while Kinder Morgan Inc trades at $32.52 (market cap $71.64B). The key difference: GSK plc is the larger of the two by market cap, and Kinder Morgan Inc pays the higher dividend (3.65%). Which is the better fit depends on your goals.
| GSK | KMI | |
|---|---|---|
Market Cap | $101.34B | $71.64B |
Sector | Health | Energy |
52-Week High | $61.18 | $34.31 |
52-Week Low | $36.20 | $25.84 |
Enterprise Value | $121.95B | $103.51B |
Dividend Yield | 3.49% | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Kinder Morgan (KMI) trades at $32.54, up 0.93% with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with revenue growth to $16.94B in 2025 and improving profit margins of 18.04%. Recent earnings show beats in Q4 2025 and Q1 2026, while analyst consensus is mixed with 47% buy ratings. The stock benefits from stable cash flows supported by fee-based contracts and a $10.1B project backlog focused on natural gas infrastructure.
KMI presents a compelling investment case with stable dividend income and growth potential from LNG and power demand. Risks include commodity price volatility and high debt levels. The stock offers value with reasonable valuation multiples and strong cash flow generation, though investors should monitor execution of growth projects and energy market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
